OPKO Health, Inc. entered into an amendment to its Note Purchase Agreement on August 13, 2026, issuing $125 million in additional senior secured notes maturing July 17, 2044. Interest accrues at SOFR plus 7.5% with a 4.0% floor and is payable quarterly using profit share payments from EirGen Pharma’s Pfizer arrangement for mazdutide sales in China. If those royalties are insufficient, interest is paid from Mazdutide Payments secured by an Eli Lilly license, capped at $187.5 million, with any excess applied to principal reduction. The company operates in the biotechnology and healthcare diagnostics industry.

OPKO Health, Inc. reported second quarter 2026 financial results, with consolidated total revenues of $163.5 million compared to $156.8 million in the prior year period. The company's operating loss for the second quarter was $7.0 million, an improvement from a $60.0 million operating loss in the same period in 2025. Net loss per share of $0.01 per share was reported for the second quarter. OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company focused on delivering next-generation solutions for serious diseases across global markets.